After Plunging 37.5% in 4 Weeks, Here's Why the Trend Might Reverse for Pulmonx ( LUNG )
Pulmonx (LUNG) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
Pulmonx ( LUNG ) Q2 Revenue Rises 15%
Pulmonx ( NASDAQ:LUNG ) , a medical technology firm specializing in minimally invasive treatments for severe lung diseases, reported earnings for Q2 2025 on July 30, 2025. The company topped revenue expectations with $23.9 million in GAAP revenue, just above the $23.74 million analyst consensus ( ...
Nasdaq Surges Over 1%; Microsoft Posts Upbeat Earnings - Align Technology ( NASDAQ:ALGN ) , GRI Bio ( NASDAQ:GRI )
U.S. stocks traded higher this morning, with the Nasdaq Composite gaining more than 1% on Thursday. Following the market opening Thursday, the Dow traded up 0.24% to 44,566.33 while the NASDAQ rose 1.26% to 21,395.66. The S&P 500 also rose, gaining, 0.76% to 6,411.57.
Pulmonx Corporation ( LUNG ) Reports Q2 Loss, Beats Revenue Estimates
Pulmonx (LUNG) delivered earnings and revenue surprises of +5.00% and +1.25%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Pulmonx to Report Second Quarter 2025 Financial Results on July 30, 2025
REDWOOD CITY, Calif., July 16, 2025 ( GLOBE NEWSWIRE ) -- Pulmonx Corporation ( Nasdaq: LUNG ) ( "Pulmonx" or the "Company" ) , a global leader in minimally invasive treatments for lung disease, today announced that it will release financial results for the second quarter of 2025 after the close ...
Pulmonx to Report Second Quarter 2025 Financial Results on July 30, 2025 - Pulmonx ( NASDAQ:LUNG )
REDWOOD CITY, Calif., July 16, 2025 ( GLOBE NEWSWIRE ) -- Pulmonx Corporation LUNG ( "Pulmonx" or the "Company" ) , a global leader in minimally invasive treatments for lung disease, today announced that it will release financial results for the second quarter of 2025 after the close of trading ...
Pulmonx Corporation ( LUNG ) Reports Q1 Loss, Tops Revenue Estimates
Pulmonx (LUNG) delivered earnings and revenue surprises of 2.70% and 3.46%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
Pulmonx to Report First Quarter 2025 Financial Results on April 30, 2025
REDWOOD CITY, Calif., April 16, 2025 ( GLOBE NEWSWIRE ) -- Pulmonx Corporation ( Nasdaq: LUNG ) ( "Pulmonx" ) , a global leader in minimally invasive treatments for lung disease, today announced that it will release financial results for the first quarter of 2025 after the close of trading on ...
P3 Health Partners ( PIII ) Stock Jumps 8.9%: Will It Continue to Soar?
P3 Health Partners (PIII) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Veeva ( VEEV ) Moves 3.7% Higher: Will This Strength Last?
Veeva (VEEV) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.
EDAP Reports Record HIFU Fourth Quarter and Full-Year 2024 Results
• Record full-year 2024 HIFU revenue of USD 25.7 million, an increase of 15.3% over full-year 2023 • Record Q4 2024 HIFU revenue of USD 9.3 million, an increase of 15.0% over Q4 2023 • U.S.
This Pulmonx Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday - Karman Holdings ( NYSE:KRMN ) , Aardvark Therapeutics ( NASDAQ:AARD )
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page. Jefferies analyst Linda Tsai initiated coverage on SailPoint, Inc.
Top 3 Health Care Stocks You May Want To Dump In February - Pulmonx ( NASDAQ:LUNG ) , Pediatrix Medical Group ( NYSE:MD )
As of Feb. 20, 2025, three stocks in the health care sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions. The RSI is a momentum indicator, which compares a stock's strength on days when prices go up to its strength on days when ...
Pulmonx Corporation ( LUNG ) Reports Q4 Loss, Tops Revenue Estimates
Pulmonx (LUNG) delivered earnings and revenue surprises of 23.26% and 4.95%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?
Phreesia ( PHR ) Moves 5.6% Higher: Will This Strength Last?
Phreesia (PHR) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Pulmonx to Present at the Citi 2025 Unplugged Medtech and Life Sciences Access Day
REDWOOD CITY, Calif., Feb. 13, 2025 ( GLOBE NEWSWIRE ) -- Pulmonx Corporation ( Nasdaq: LUNG ) ( "Pulmonx" ) a global leader in minimally invasive treatments for severe lung disease, today announced the company will be participating in a fireside chat at the Citi 2025 Unplugged Medtech and Life ...
Does Pulmonx ( LUNG ) Have the Potential to Rally 117.74% as Wall Street Analysts Expect?
The consensus price target hints at an 117.7% upside potential for Pulmonx (LUNG). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Pulmonx to Present at the Piper Sandler 36th Annual Healthcare Conference
REDWOOD CITY, Calif., Nov. 20, 2024 ( GLOBE NEWSWIRE ) -- Pulmonx Corporation ( Nasdaq: LUNG ) ( "Pulmonx" ) a global leader in minimally invasive treatments for severe lung disease, today announced the company will be participating in a fireside chat at the Piper Sandler 36th Annual Healthcare ...
Pulmonx to Present at the Piper Sandler 36th Annual Healthcare Conference - Pulmonx ( NASDAQ:LUNG )
REDWOOD CITY, Calif., Nov. 20, 2024 ( GLOBE NEWSWIRE ) -- Pulmonx Corporation LUNG ( "Pulmonx" ) a global leader in minimally invasive treatments for severe lung disease, today announced the company will be participating in a fireside chat at the Piper Sandler 36th Annual Healthcare Conference ...
Wall Street Analysts Predict an 89.61% Upside in Pulmonx ( LUNG ) : Here's What You Should Know
The average of price targets set by Wall Street analysts indicates a potential upside of 89.6% in Pulmonx (LUNG). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Pulmonx Corporation ( LUNG ) Reports Q3 Loss, Misses Revenue Estimates
Pulmonx (LUNG) delivered earnings and revenue surprises of 16.28% and 0.02%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?
Pulmonx to Present at the 2024 Wells Fargo Healthcare Conference
REDWOOD CITY, Calif., Aug. 22, 2024 ( GLOBE NEWSWIRE ) -- Pulmonx Corporation ( Nasdaq: LUNG ) ( "Pulmonx" ) a global leader in minimally invasive treatments for severe lung disease, today announced the company will be participating in a fireside chat at the 2024 Wells Fargo Healthcare ...
Pulmonx Corporation ( LUNG ) Reports Q2 Loss, Tops Revenue Estimates
Pulmonx (LUNG) delivered earnings and revenue surprises of 4.88% and 2.72%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Pulmonx to Present at the Canaccord Genuity 44th Annual Growth Conference
REDWOOD CITY, Calif., July 29, 2024 ( GLOBE NEWSWIRE ) -- Pulmonx Corporation ( Nasdaq: LUNG ) ( "Pulmonx" ) , a global leader in minimally invasive treatments for severe lung disease, today announced the company will present at the upcoming Canaccord Genuity 44th Annual Growth Conference in ...
Pulmonx to Report Second Quarter 2024 Financial Results on July 31, 2024
REDWOOD CITY, Calif., July 10, 2024 ( GLOBE NEWSWIRE ) -- Pulmonx Corporation ( Nasdaq: LUNG ) ( "Pulmonx" ) , a global leader in minimally invasive treatments for lung disease, today announced that it will release financial results for the second quarter of 2024 after the close of trading on ...
5 Medical Info Systems Stock to Buy for a Stable Portfolio - Enovis ( NYSE:ENOV ) , Hims & Hers Health ( NYSE:HIMS )
The medical info systems industry is set to thrive in the second half of 2024 due to the growing demand for contactless services. The industry witnessed exponential growth during the pandemic era. Even in the post-pandemic period, remote healthcare, a paperless environment and distant treatment ...
5 Medical Info Systems Stock to Buy for a Stable Portfolio
We have narrowed our search to five medical info systems stocks. These are: HIMS, ENOV, LUNG, PHR, LAB.
How Much Upside is Left in Pulmonx ( LUNG ) ? Wall Street Analysts Think 80.3%
The consensus price target hints at an 80.3% upside potential for Pulmonx (LUNG). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
5 Medical Info Systems Stocks to Buy for Stable Returns
We have narrowed our search to five medical info systems stocks that have strong growth potential for 2024. These stocks are: HIMS, BFLY, ENOV, LUNG, DH.
Pulmonx Announces Inducement Grants under Nasdaq Listing Rule 5635 ( c ) ( 4 ) - Pulmonx ( NASDAQ:LUNG )
REDWOOD CITY, Calif., May 06, 2024 ( GLOBE NEWSWIRE ) -- Pulmonx Corporation LUNG ( "Pulmonx" or the "Company" ) , a global leader in minimally invasive treatments for lung disease, today announced that the Compensation Committee of the Board of Directors of Pulmonx ( the "Compensation ...
Pulmonx Announces Inducement Grants under Nasdaq Listing Rule 5635 ( c ) ( 4 )
REDWOOD CITY, Calif., May 06, 2024 ( GLOBE NEWSWIRE ) -- Pulmonx Corporation ( Nasdaq: LUNG ) ( "Pulmonx" or the "Company" ) , a global leader in minimally invasive treatments for lung disease, today announced that the Compensation Committee of the Board of Directors of Pulmonx ( the ...
Wall Street Analysts See a 56.11% Upside in Pulmonx ( LUNG ) : Can the Stock Really Move This High?
The consensus price target hints at a 56.1% upside potential for Pulmonx (LUNG). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
C.H. Robinson Worldwide Posts Upbeat Results, Joins Avis Budget Group, Qualcomm, BorgWarner, Moderna And Other Big Stocks Moving Higher On Thursday - C.H. Robinson Worldwide ( NASDAQ:CHRW ) , Qualcomm ( NASDAQ:QCOM )
U.S. stocks were higher, with the Dow Jones index gaining over 50 points on Thursday. Shares of C.H. Robinson Worldwide, Inc. CHRW rose sharply during Thursday's session after the company reported better-than-expected first-quarter financial results. C.H.
Pulmonx Corporation ( LUNG ) Reports Q1 Loss, Tops Revenue Estimates
Pulmonx (LUNG) delivered earnings and revenue surprises of 16.28% and 7.52%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
Pulmonx Announces Appointment of Mehul Joshi as Chief Financial Officer - Pulmonx ( NASDAQ:LUNG )
REDWOOD CITY, Calif., April 02, 2024 ( GLOBE NEWSWIRE ) -- Pulmonx Corporation LUNG ( "Pulmonx" or the "Company" ) , a global leader in minimally invasive treatments for lung disease, today announced the appointment of Mehul Joshi as Chief Financial Officer, effective April 3, 2024.
Pulmonx Announces Inducement Grants under Nasdaq Listing Rule 5635 ( c ) ( 4 )
REDWOOD CITY, Calif., March 15, 2024 ( GLOBE NEWSWIRE ) -- Pulmonx Corporation ( Nasdaq: LUNG ) ( "Pulmonx" or the "Company" ) , a global leader in minimally invasive treatments for lung disease, today announced the inducement grant of equity awards to Steve Williamson, its newly-hired President ...
Omnicell ( OMCL ) Tops Q4 Earnings and Revenue Estimates
Omnicell (OMCL) delivered earnings and revenue surprises of 94.12% and 1.11%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
3 Penny Stocks Under $3 To Watch Right Now
As an aggressive subset of equities, penny stocks offer patient investors occasional lottery ticket-like returns. However, the market gyrations around news and events also invite risk. This guide explores the fundamentals of penny stocks, how announcements drive explosive moves, and resources to ...
The Honest Company Announces Appointment of Michael Barkley, Alissa Hsu Lynch, and Andrea Turner to the Board of Directors
LOS ANGELES, Dec. 11, 2023 ( GLOBE NEWSWIRE ) -- The Honest Company ( NASDAQ: HNST ) , a digitally-native consumer products company dedicated to creating clean- and sustainably-designed products spanning baby care, beauty, personal care, wellness and household care, today announced that Michael ...
The Honest Company Announces Appointment of Michael Barkley, Alissa Hsu Lynch, and Andrea Turner to the Board of Directors - Pulmonx ( NASDAQ:LUNG ) , Honest Co ( NASDAQ:HNST )
LOS ANGELES, Dec. 11, 2023 ( GLOBE NEWSWIRE ) -- The Honest Company HNST, a digitally-native consumer products company dedicated to creating clean- and sustainably-designed products spanning baby care, beauty, personal care, wellness and household care, today announced that Michael Barkley, ...
Arista Networks, JinkoSolar, Repligen, Shutterstock And Other Big Stocks Moving Higher On Tuesday - Arista Networks ( NYSE:ANET ) , Ardelyx ( NASDAQ:ARDX )
U.S. stocks traded lower, with the Dow Jones falling more than 50 points on Tuesday. Here are some major stocks recording gains in today's session. Verve Therapeutics, Inc. VERV gained 27% to $11.95.
Pulmonx Corporation ( LUNG ) Reports Q3 Loss, Tops Revenue Estimates
Pulmonx Corporation (LUNG) delivered earnings and revenue surprises of 13.33% and 10.67%, respectively, for the quarter ended September 2023. Do the numbers hold clues to what lies ahead for the stock?
Pulmonx to Report Third Quarter 2023 Financial Results on October 30, 2023 - Pulmonx ( NASDAQ:LUNG )
REDWOOD CITY, Calif., Oct. 16, 2023 ( GLOBE NEWSWIRE ) -- Pulmonx Corporation LUNG ( "Pulmonx" ) , a global leader in minimally invasive treatments for lung disease, today announced that it will release financial results for the third quarter of 2023 after the close of trading on Monday, October ...
Pulmonx Announces CFO Transition and Record Preliminary Third Quarter 2023 Revenue - Pulmonx ( NASDAQ:LUNG )
Derrick Sung steps down from his position as Chief Financial Officer to pursue another opportunity; John McKune appointed Interim Chief Financial Officer Preliminary, unaudited third quarter 2023 revenue expected to be approximately $17.6 million
Pulmonx Corporation ( LUNG ) Reports Q2 Loss, Tops Revenue Estimates
Pulmonx Corporation (LUNG) delivered earnings and revenue surprises of 0% and 8.07%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Pulmonx to Report Second Quarter 2023 Financial Results on August 2, 2023
REDWOOD CITY, Calif., July 19, 2023 ( GLOBE NEWSWIRE ) -- Pulmonx Corporation ( Nasdaq: LUNG ) ( "Pulmonx" ) , a global leader in minimally invasive treatments for lung disease, today announced that it will release financial results for the second quarter of 2023 after the close of trading on ...
Pulmonx to Report Second Quarter 2023 Financial Results on August 2, 2023
REDWOOD CITY, Calif., July 17, 2023 ( GLOBE NEWSWIRE ) -- Pulmonx Corporation ( Nasdaq: LUNG ) ( "Pulmonx" ) , a global leader in minimally invasive treatments for lung disease, today announced that it will release financial results for the second quarter of 2023 after the close of trading on ...
Pulmonx Corporation ( LUNG ) Reports Q1 Loss, Tops Revenue Estimates
Pulmonx Corporation (LUNG) delivered earnings and revenue surprises of 2.33% and 6.20%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Top 5 Health Care Stocks That You May Want To Dump In Q1 2023 - Genelux ( NASDAQ:GNLX ) , Ambrx Biopharma ( NYSE:AMAM )
The most overbought stocks in the health care sector presents an opportunity to go short on these overvalued companies. The RSI is a momentum indicator, which compares a stock's strength on days when prices go up to its strength on days when prices go down.
Stocks making the biggest moves midday: Union Pacific, Fisker, Tesla, Zillow and more
Union Pacific soared on news of a leadership change.
